REALITY (REAL world evidence preeclampsIa sTudY)
Research type
Research Study
Full title
A multicenter, prospective, observational study to evaluate the use of the sFlt-1/PlGF ratio in the risk stratification of pregnant women with the presence of preeclampsia or related signs and symptoms in current clinical practice.
IRAS ID
297659
Contact name
Janine de Haan
Contact email
Sponsor organisation
Roche Diagnostics International Limited
Duration of Study in the UK
1 years, 10 months, 1 days
Research summary
The purpose of this study is to:
Investigate further exactly how useful the blood test (sFlt-1/PlGF ratio) is to identify mothers who are at risk and not at risk of developing problems with their pregnancy or baby due to preeclampsia.
This blood test, technically known as the sFlt-1/PlGF ratio (Soluble Fms-like tyrosine kinase 1/Placental Growth Factor), helps doctors to manage pregnancy in women who have, or maybe are at risk of preeclampsia later in their pregnancy.Preeclampsia is a condition which some mothers develop later in pregnancy identified by a raised blood pressure and increased protein in the urine. The condition resolves after birth. However, in some mothers it can cause problems for the pregnancy and baby.
The study is purely observational, meaning no additional assessments, attests or procedures are requested outside of the patient's standard care. The blood test is taken as part of the patient's routine care as determined by her doctor to manage her pregnancy and will be the same as if she decides not to participate in the study.
REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
21/EM/0195
Date of REC Opinion
10 Aug 2021
REC opinion
Favourable Opinion